The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2020

Filed:

Jan. 02, 2018
Applicant:

Alba Therapeutics Corporation, Baltimore, MD (US);

Inventors:

Sefik Alkan, Baltimore, MD (US);

Amir Tamiz, Silver Spring, MD (US);

Kelly Marie Kitchens, Laurel, MD (US);

Malarvizhi Durai, Ellicott City, MD (US);

Neil Poloso, Rockville, MD (US);

Rosa A. Carrasco, Baltimore, MD (US);

Assignee:

ALBA THERAPEUTICS CORPORATION, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); A61K 45/06 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); C07K 5/09 (2006.01); C07K 5/093 (2006.01); C07K 5/097 (2006.01); C07K 5/103 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/06 (2013.01); A61K 38/06 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); C07K 5/081 (2013.01); C07K 5/0804 (2013.01); C07K 5/0806 (2013.01); C07K 5/0808 (2013.01); C07K 5/0812 (2013.01); C07K 5/0815 (2013.01); C07K 5/0817 (2013.01); C07K 5/0819 (2013.01); C07K 5/0821 (2013.01); C07K 5/101 (2013.01); C07K 5/1008 (2013.01); A61K 38/00 (2013.01);
Abstract

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.


Find Patent Forward Citations

Loading…